When we go to the pharmacy to buy medicine, what we receive are boxes of tablets, individual capsules, or vials of injectable solutions. We are accustomed to calling them “medicines,” yet we seldom stop to consider: Where do these pharmaceutical products, as they ultimately appear before us, actually come from? What determines their efficacy and safety? The answer lies in two key concepts: **active pharmaceutical ingredients** and **pharmaceutical preparations**.

1. What is an active pharmaceutical ingredient (API)?

An active pharmaceutical ingredient, whose full English name is Active Pharmaceutical Ingredient, is abbreviated as API. According to the authoritative definition, an active pharmaceutical ingredient (API) refers to the raw drug substance used in the manufacture of various dosage forms and constitutes the active component of the formulation. It comprises various substances—such as powders, crystals, and extracts—prepared through chemical synthesis, plant extraction, or biotechnology.

Simply put, the active pharmaceutical ingredient is the core component in a drug that actually exerts the therapeutic effect—it is what kills bacteria, lowers blood pressure, and relieves pain. The definition in ICH Q7A is more rigorous: an active pharmaceutical ingredient (API) is “any substance or mixture of substances intended to be used in the manufacture of a drug product, and which, when used in that context, becomes an active moiety of the drug.”

However, one crucial point must be made clear: the active pharmaceutical ingredient is a “raw material” and cannot be taken directly by patients. High‑purity active pharmaceutical ingredients may exist as powders, crystals, or even extracts; in their raw form, they are neither orally ingestible nor suitable for precise dosing.

2. What is a dosage form?

A dosage form refers to the final pharmaceutical form we commonly know, such as “tablets,” “capsules,” and “injection solutions.” It is the final product, ready for direct administration by patients, obtained by combining the active pharmaceutical ingredient with various excipients—such as fillers, binders, disintegrants, and coating materials—according to scientifically optimized proportions and processed through a series of pharmaceutical manufacturing steps.

If the active pharmaceutical ingredient is the “flour,” then the finished dosage form is the baked “bread”—flour is the soul of bread, yet no one would ever eat flour on its own.

3. The Core Relationship Between APIs and Preparations

The relationship between APIs and preparations can be understood at three levels:

First, the API is the “source of life” for the preparation. Whether a pharmaceutical product is effective first depends on whether its active pharmaceutical ingredient is efficacious, meets the required purity standards, and has impurities strictly controlled. If the active pharmaceutical ingredient fails to meet quality standards, even the most advanced formulation technologies cannot “safeguard” the safety and efficacy of the final drug product. The quality of active pharmaceutical ingredients directly determines the quality of the finished dosage forms.

Second, the active pharmaceutical ingredient is a “semi-finished product,” while the dosage form is the “finished product.”

Active pharmaceutical ingredients are a midstream product in the pharmaceutical industry value chain—upstream lie pharmaceutical intermediates, while downstream are finished dosage forms. Active pharmaceutical ingredient (API) manufacturers, such as Shanghai Hengyuehe Biopharmaceutical Co., Ltd., convert intermediates into high‑purity APIs through chemical synthesis or biotechnology and then supply them to formulation companies. These formulation companies subsequently combine the APIs with excipients and, via processes such as granulation, tableting, coating, and filling, produce finished dosage forms ready for patient use.

Third, APIs and finished dosage forms are subject to “joint review” at the regulatory level.

According to the regulations of the National Medical Products Administration, active pharmaceutical ingredients, pharmaceutical excipients, and packaging materials for drugs are subject to a system of linked review and approval. At the time of registration, pharmaceutical formulation manufacturers are required to submit, together with their application, quality documentation for the active pharmaceutical ingredients they use. The status of an active pharmaceutical ingredient on the registration platform is indicated by “A” (approved) or “I” (not approved). This means that, in regulatory terms, the active pharmaceutical ingredient and the finished dosage form are “tied” together—if the formulation uses an不合格 API, the entire drug product will fail to obtain marketing authorization.

4. From Active Pharmaceutical Ingredient to Finished Dosage Form: A Long Journey

Many people are unaware that it is an extremely long process for an active pharmaceutical ingredient to go from development to final formulation and, ultimately, to market.

Take generic drugs as an example: it typically takes 5 to 8 years from the start of R&D to obtaining approval for an active pharmaceutical ingredient, with the registration and review phase alone accounting for about 3 to 5 years. Registration fees range from five million yuan at the lower end to over ten million yuan at the upper end. After the active pharmaceutical ingredient (API) has been developed, it must be handed over to a formulation‑manufacturing company for formulation‑technology development and marketing‑approval application. Assuming there are no patent or litigation issues, the entire process will still take **3 to 4 years**. The entire process, from active pharmaceutical ingredient development to finished‑product launch, typically takes six to seven years. Meanwhile, the timeline for patented new drugs is even longer.

In contrast, the R&D cycle for formulated products typically lasts one to two years, and registration costs can exceed one million yuan. This also underscores, from one perspective, that the development of active pharmaceutical ingredients is the most challenging hurdle in the entire drug‑development process.

5. The Global Landscape of the Active Pharmaceutical Ingredient Industry

Active pharmaceutical ingredients are not only the “source of life” for every drug, but also constitute a vast global industry.

According to market research firms, the global API market is estimated to be valued between US$177.5 billion and US$256.4 billion in 2025, and is projected to reach US$307.8 billion to US$376.2 billion by 2032. As a major global supplier of active pharmaceutical ingredients (APIs), China recorded total API and intermediate import–export trade valued at US$55.25 billion in 2025, with exports accounting for US$42.87 billion. In the first half of 2025, the export value of active pharmaceutical ingredients and pharmaceutical intermediates reached US$22.15 billion, up 3.8% year on year. China’s active pharmaceutical ingredient (API) industry is transitioning from quantitative expansion to a qualitative leap.

The next time you pick up a box of medication, take a moment to reflect: behind that small pill lies years of relentless research and development by API scientists, the unwavering pursuit of excellence in every production step by formulation engineers, and the rigorous quality control exercised by regulatory authorities over each batch. Active pharmaceutical ingredients are the “core” of a drug, while dosage forms are its “form.” Without high-quality active pharmaceutical ingredients, there can be no safe and effective drug formulations; and without sophisticated formulation technologies, even the finest APIs cannot bring therapeutic benefits to patients. Shanghai Hengyuehe Biopharmaceutical Co., Ltd. has been deeply engaged in the pharmaceutical intermediates and active pharmaceutical ingredient (API) sectors for more than a decade, dedicated to establishing the most solid quality foundation for every finished dosage form—because safeguarding API quality is, in essence, protecting the lives and health of millions of patients.